Venture Capital

As the grid faces a crisis from decentralization, data centers, and decarbonization, G&W Electric is launching a new intelligence hub to find solutions.

A new partnership with a NASA veteran's VC firm aims to accelerate startups at UCF, turning space-grade innovations into terrestrial solutions.

The Jewish Theological Seminary appoints engagement expert Rabbi Mike Uram, signaling a strategic shift to modernize and expand its reach in a changing world.

Alkeus Pharmaceuticals will present crucial data on its oral drug for Stargardt disease, a leading cause of juvenile blindness with no current cure.

The logistics firm's recognition as a climate leader highlights an industry race where sustainability is now a key competitive and strategic advantage.

A Boston biotech is using AI and targeted mRNA to program cells inside the body, aiming to make complex CAR T treatments safer and universally accessible.

Vortex Energy is advancing its Robinsons River project, aiming to turn ancient salt deposits into vital storage for Canada's burgeoning hydrogen economy.

A new study shows high success for VVT Med's ScleroSafe varicose vein treatment, but a closer look reveals the need for more long-term data.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

Swiss medtech firm CorFlow is tackling a major post-heart attack complication with two pivotal trials, aiming to create a new standard of care.

TIME recognizes Fora's disruptive platform, which empowers thousands of new entrepreneurs to redefine the travel advisor role with AI-supercharged expertise.

With new funding, DISA Technologies is scaling its unique HPSA™ tech to secure US supply chains and remediate the toxic legacy of abandoned uranium mines.

Former HHS Secretary Tommy Thompson joins Vector Science & Therapeutics, leveraging his political clout to advance a novel transdermal drug delivery platform.

New research reveals food and beverage brands are misallocating ad spend by targeting a non-existent average consumer, ignoring three distinct buyer types.

With double-digit growth and key US acquisitions, ESTEVE is rapidly expanding. But it's the firm's B Corp status that may redefine success in pharma.

The Canadian miner's new OTCQB listing aims to attract American capital, fueling exploration of its promising gold and copper assets in British Columbia.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

The £87M take-private deal merges VertiGIS's applications with 1Spatial's data expertise, aiming to dominate the AI-driven geospatial solutions market.

With a $1.8M grant, AltaLink is using real-time weather data to unlock hidden capacity in power lines, saving money and boosting grid reliability.

NETGEAR smashed Q1 profit forecasts, driven by its booming enterprise unit. The company's strategic pivot to high-margin products is paying off.